{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06300307",
            "orgStudyIdInfo": {
                "id": "CT-ATX-01-DM1-1.1"
            },
            "organization": {
                "fullName": "ARTHEx Biotech S.L.",
                "class": "INDUSTRY"
            },
            "briefTitle": "Study of ATX-01 in Participants With DM1",
            "officialTitle": "A Phase 1/2a Double-Blind, Placebo-controlled, Single- and Multiple Ascending Dose Study to Assess the Safety, Tolerability, PK, PD and Efficacy of IV Administration of ATX-01 In Male and Female Participants Aged 18 to 64 With Classic DM1",
            "acronym": "ArthemiR",
            "therapeuticArea": [
                "Other"
            ],
            "study": "study-of-atx-in-participants-with"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "startDateStruct": {
                "date": "2024-05-24",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-12",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-12",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-02-26",
            "studyFirstSubmitQcDate": "2024-03-02",
            "studyFirstPostDateStruct": {
                "date": "2024-03-08",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-02",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-03",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "ARTHEx Biotech S.L.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The goal of this clinical trial is to test ATX-01 in participants with myotonic dystrophy type 1 (DM1). The main question it aims to answer is if ATX-01 is safe and well tolerated. The trial will compare the safety and tolerability of ATX-01 and a matching placebo.\n\nThere will be a single-ascending dose part of the trial and a multiple-ascending dose part. In the single-ascending dose, participants will receive one dose of ATX-01 or placebo. In the multiple-ascending dose part, participants will receive three doses of ATX-01 or placebo.\n\nATX-01 is a novel anti-miR (synthetic single stranded oligonucleotide) that inhibits a microRNA called miR-23b."
        },
        "conditionsModule": {
            "conditions": [
                "Myotonic Dystrophy 1"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "TRIPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 56,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "ATX-01",
                    "type": "EXPERIMENTAL",
                    "description": "ATX-01 is a formulation of the anti-microRNA 23b (anti-miR-23b), known as X82108, a novel type of antisense oligonucleotide",
                    "interventionNames": [
                        "Drug: ATX-01"
                    ]
                },
                {
                    "label": "Placebo",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Placebo to ATX-01",
                    "interventionNames": [
                        "Drug: Placebo"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "ATX-01",
                    "description": "Solution for infusion",
                    "armGroupLabels": [
                        "ATX-01"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo",
                    "description": "Solution for infusion",
                    "armGroupLabels": [
                        "Placebo"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Incidence of adverse events",
                    "description": "To evaluate the safety and tolerability of ATX-01 in adult participants with DM1",
                    "timeFrame": "Up to 120 days"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Incidence of clinically significant changes in laboratory assessments, electrocardiograms (ECGs), vital signs, suicidal ideation and behavior",
                    "description": "To further evaluate the safety and tolerability of ATX-01 in adult participants with DM1",
                    "timeFrame": "Up to 120 days"
                },
                {
                    "measure": "Maximum observed plasma concentration (Cmax) of ATX-01",
                    "timeFrame": "Up to 48 hours post-dose"
                },
                {
                    "measure": "Area under the plasma concentration-time curve (AUC) of ATX-01",
                    "timeFrame": "Up to 48 hours post-dose"
                },
                {
                    "measure": "Video hand opening time",
                    "description": "To evaluate the efficacy of ATX-01 on myotonia in participants with DM1",
                    "timeFrame": "Change from baseline up to 120 days"
                },
                {
                    "measure": "Change from baseline in ankle dorsiflexion strength by quantitative myometry",
                    "description": "To evaluate the effects of ATX-01 in participants with DM1 on ankle dorsiflexion strength",
                    "timeFrame": "Change from baseline up to 120 days"
                },
                {
                    "measure": "Change from baseline in Impact on Activities of Daily Living questionnaire item scores",
                    "description": "The Impact on Activities of Daily Living questionnaire is a 7-item patient-reported outcome designed to evaluate the impact of ATX-01 on activities of daily living in participants with DM1.",
                    "timeFrame": "Change from baseline up to 120 days"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Key Inclusion Criteria:\n\n* Participants with a documented clinical diagnosis of DM1 (CTG expansion of \\>150 repeats in DMPK gene measured in peripheral blood mononuclear cells)\n* Ambulatory, defined as able to complete a 10-meter walk/run test at screening without the use of assistive devices such as canes, walkers, or orthoses, except for ankle-foot orthoses\n* Presence for \\>3 seconds of grip myotonia as confirmed by a central reader\n\nKey Exclusion Criteria:\n\n* Participants with congenital DM1\n* Medical Research Council Muscle Scale score of less than 4 on ankle dorsiflexion or significant tibialis anterior atrophy that prevents a muscle biopsy\n* Use of mexiletine or other agent for myotonia within 21 days or 5 half-lives, whichever is longer, prior to screening",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "64 Years",
            "stdAges": [
                "ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Project Manager",
                    "role": "CONTACT",
                    "phone": "+34676229821",
                    "email": "clinical@arthexbiotech.com"
                }
            ],
            "locations": [
                {
                    "facility": "University of Florida",
                    "status": "RECRUITING",
                    "city": "Gainesville",
                    "state": "Florida",
                    "zip": "32610",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Beverly (Mackenzie) Brooks, ACRP-CCRC",
                            "role": "CONTACT",
                            "email": "beverly.brooks@neurology.ufl.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.65163,
                        "lon": -82.32483
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "UNDECIDED"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009223",
                    "term": "Myotonic Dystrophy"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009136",
                    "term": "Muscular Dystrophies"
                },
                {
                    "id": "D000020966",
                    "term": "Muscular Disorders, Atrophic"
                },
                {
                    "id": "D000009135",
                    "term": "Muscular Diseases"
                },
                {
                    "id": "D000009140",
                    "term": "Musculoskeletal Diseases"
                },
                {
                    "id": "D000020967",
                    "term": "Myotonic Disorders"
                },
                {
                    "id": "D000020271",
                    "term": "Heredodegenerative Disorders, Nervous System"
                },
                {
                    "id": "D000019636",
                    "term": "Neurodegenerative Diseases"
                },
                {
                    "id": "D000009422",
                    "term": "Nervous System Diseases"
                },
                {
                    "id": "D000009468",
                    "term": "Neuromuscular Diseases"
                },
                {
                    "id": "D000030342",
                    "term": "Genetic Diseases, Inborn"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M12175",
                    "name": "Myotonic Dystrophy",
                    "asFound": "Myotonic Dystrophy",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12093",
                    "name": "Muscular Dystrophies",
                    "relevance": "LOW"
                },
                {
                    "id": "M12092",
                    "name": "Muscular Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M4589",
                    "name": "Atrophy",
                    "relevance": "LOW"
                },
                {
                    "id": "M22697",
                    "name": "Muscular Disorders, Atrophic",
                    "relevance": "LOW"
                },
                {
                    "id": "M12097",
                    "name": "Musculoskeletal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M22698",
                    "name": "Myotonic Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M22092",
                    "name": "Heredodegenerative Disorders, Nervous System",
                    "relevance": "LOW"
                },
                {
                    "id": "M21558",
                    "name": "Neurodegenerative Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M12411",
                    "name": "Neuromuscular Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M23686",
                    "name": "Genetic Diseases, Inborn",
                    "relevance": "LOW"
                },
                {
                    "id": "T4024",
                    "name": "Myotonic Dystrophy",
                    "asFound": "Myotonic Dystrophy",
                    "relevance": "HIGH"
                },
                {
                    "id": "T4025",
                    "name": "Myotonic Dystrophy Type 1",
                    "asFound": "Myotonic Dystrophy 1",
                    "relevance": "HIGH"
                },
                {
                    "id": "T3963",
                    "name": "Muscular Dystrophy",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC05",
                    "name": "Musculoskeletal Diseases"
                },
                {
                    "abbrev": "BC10",
                    "name": "Nervous System Diseases"
                },
                {
                    "abbrev": "BC16",
                    "name": "Diseases and Abnormalities at or Before Birth"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M21860",
                    "name": "Pharmaceutical Solutions",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "PhSol",
                    "name": "Pharmaceutical Solutions"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}